|
A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche Pharma AG (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Pierre Fabre |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
Consulting or Advisory Role - Janssen (Inst) |
Research Funding - Janssen (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis |